Mirae Asset Capital Life Science, Inc.

Thesis

Mirae Asset Capital Life Science, Inc. is a US-based venture capital firm established in 2023, dedicated to life science investments. Operating with an inaugural fund of $50 million, Mirae Asset Capital Life Science Inception I, LP, the firm targets private life-science and biotechnology companies. Their investment strategy prioritizes companies in the life sciences sector, with a strong emphasis on biotechnology, aiming for clinical proof of concept. They are modality-agnostic for therapeutics and opportunistic for diagnostics, with a keen interest in digital health applications leveraging AI and machine learning for drug discovery and protein engineering. The firm concentrates on five core therapeutic areas: Oncology, Immunology, Cardiovascular/Metabolic Disease, Central Nervous System/Ophthalmology, and Rare/Genetic Diseases. Mirae Asset Capital Life Science primarily invests in companies at the Seed, Series A, Series B, and Series C stages, with a focus on Series A/B companies entering the clinic. They maintain a global investment strategy with a strong emphasis on North America, identifying high-value assets outside the U.S. for development into U.S. newcos. The typical check size per investment deal ranges from $1 million to $10 million.

Related lists

• Seed-stage AI investors
• Seed-stage Healthcare investors
• Series A AI investors